Shionogi & Co (TYO:4507) revised its dividend forecast for the fiscal year ending March 31, 2025, increasing the year-end dividend to 33 yen per share, up from the previous forecast of 29 yen, according to a Thursday filing on the Tokyo Stock Exchange.
The company now expects annual dividends of 184 yen per share, an increase of 24 yen from the prior year, reflecting 13 consecutive years of dividend growth.
Shionogi's strong performance, driven by the success of its treatments such as Xocova for COVID-19 and Xofluza for influenza, as well as the global expansion of its Cefiderocol sales, contributed to the revision.
The company is also advancing its growth phase, particularly with its COVID-19 treatment Ensitrelvir and HIV treatments through its ViiV Healthcare partnership.
Price (JPY): $2385.00, Change: $-35, Percent Change: -1.43%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。